• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐酸氯卡色林与生活方式咨询用于维持低热量饮食减肥效果的随机试验

A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet.

机构信息

Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Department of Psychiatry, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

出版信息

Obesity (Silver Spring). 2018 Feb;26(2):299-309. doi: 10.1002/oby.22081. Epub 2017 Dec 29.

DOI:10.1002/oby.22081
PMID:29288545
Abstract

OBJECTIVE

Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions.

METHODS

This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks.

RESULTS

At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318).

CONCLUSIONS

Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.

摘要

目的

提高减肥后的维持率仍然是一个关键挑战,可以通过长期的行为和/或药物干预来解决。

方法

本研究调查了联合行为和药物治疗在促进 137 名成年人(86.1%为女性;68.6%为黑人;BMI=37.0±5.6kg/m )减肥后维持体重(WLM)方面的疗效,这些参与者在 14 周的低热量饮食(LCD)计划中已经减轻了初始体重的≥5%(平均=9.3±2.9%)。参与者被随机分配到lorcaserin(每天两次,每次 10mg)或安慰剂组,并在 52 周内接受 16 次团体 WLM 咨询。

结果

在随机分组后 24 周时,lorcaserin 治疗组比安慰剂组有更多的参与者维持了≥5%的减重(73.9%比 57.4%;P=0.033),lorcaserin 治疗组额外减轻了 2.4±0.8kg,而安慰剂组则增加了 0.6±0.8kg(P=0.010)。然而,在第 52 周时,两组在两个主要终点上都没有差异;分别有 55.1%和 42.6%的参与者维持了≥5%的减重(P=0.110),从随机分组开始的体重增加分别为 2.0±0.8kg 和 2.5±0.8kg(P=0.630)。从 LCD 开始,两组分别维持了 7.8%和 6.6%的体重减轻(P=0.318)。

结论

在以黑人为主的参与者中,联合行为和药物治疗产生了具有临床意义的长期减肥效果。lorcaserin 最初改善了 WLM 咨询所达到的减重效果,但这种优势在 1 年内没有维持。

相似文献

1
A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet.盐酸氯卡色林与生活方式咨询用于维持低热量饮食减肥效果的随机试验
Obesity (Silver Spring). 2018 Feb;26(2):299-309. doi: 10.1002/oby.22081. Epub 2017 Dec 29.
2
A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite.氯卡色林与生活方式咨询用于维持体重减轻的随机对照试验:与情绪和压力相关的饮食、食物渴望及食欲的变化
Clin Obes. 2018 Dec;8(6):383-390. doi: 10.1111/cob.12279. Epub 2018 Sep 17.
3
Lorcaserin plus lifestyle modification for weight loss maintenance: Rationale and design for a randomized controlled trial.洛卡塞林联合生活方式改变以维持体重减轻:一项随机对照试验的原理与设计
Contemp Clin Trials. 2017 Aug;59:105-112. doi: 10.1016/j.cct.2017.06.004. Epub 2017 Jun 16.
4
Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial.体重减轻对健康相关生活质量的短期和长期变化:一项随机对照试验的结果。
Obesity (Silver Spring). 2018 Jun;26(6):985-991. doi: 10.1002/oby.22187. Epub 2018 Apr 20.
5
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.利拉鲁肽维持体重和在低热量饮食诱导体重减轻后的额外体重减轻:SCALE Maintenance 随机研究。
Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1.
6
A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.一项为期一年的用于肥胖和超重成年人减肥的lorcaserin 随机试验:BLOSSOM 试验。
J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77. doi: 10.1210/jc.2011-1256. Epub 2011 Jul 27.
7
Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.服用氯卡色林期间的早期体重减轻、饮食和运动作为第52周体重减轻结果的预测指标。
Obesity (Silver Spring). 2014 Oct;22(10):2137-46. doi: 10.1002/oby.20841. Epub 2014 Jul 18.
8
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet.一项生活方式改变和 taranabant 联合用于维持低热量饮食减肥效果的随机试验。
Obesity (Silver Spring). 2010 Dec;18(12):2301-10. doi: 10.1038/oby.2010.67. Epub 2010 Apr 8.
9
Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.氯卡色林对超重和肥胖2型糖尿病患者血糖控制的影响:第52周有反应者和无反应者的分析
Postgrad Med. 2016 Aug;128(6):591-7. doi: 10.1080/00325481.2016.1208618. Epub 2016 Jul 18.
10
Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.氯卡色林的安全性与有效性:BLOOM和BLOSSOM试验的联合分析
Postgrad Med. 2014 Oct;126(6):7-18. doi: 10.3810/pgm.2014.10.2817.

引用本文的文献

1
"Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).“抗肥胖药物”或“治疗肥胖症的药物”而非“减肥药”- 语言为何重要 - 巴西肥胖与代谢综合征研究学会(ABESO)和巴西内分泌学会(SBEM)的官方声明。
Arch Endocrinol Metab. 2023 Aug 16;67(4):e230174. doi: 10.20945/2359-4292-2023-0174.
2
5-HT Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators.5-羟色胺受体刺激在肥胖治疗中的应用:正构激动剂与变构调节剂。
Nutrients. 2023 Mar 17;15(6):1449. doi: 10.3390/nu15061449.
3
Mindful Eating, General Mindful Awareness, and Acceptance as Predictors of Weight Loss.
正念饮食、一般正念意识和接纳作为体重减轻的预测因素。
Mindfulness (N Y). 2020 Dec;11(12):2818-2827. doi: 10.1007/s12671-020-01493-5. Epub 2020 Sep 18.
4
Long-term effects of weight-reducing drugs in people with hypertension.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5.
5
Associations between causal attributions for obesity and long-term weight loss.肥胖的因果归因与长期体重减轻之间的关联。
Behav Med. 2020 Apr-Jun;46(2):87-91. doi: 10.1080/08964289.2018.1556202. Epub 2019 Jan 18.
6
Weight Bias Internalization Is Negatively Associated With Weight-Related Quality of Life in Persons Seeking Weight Loss.体重偏见内化与寻求减肥者的体重相关生活质量呈负相关。
Front Psychol. 2018 Dec 17;9:2576. doi: 10.3389/fpsyg.2018.02576. eCollection 2018.
7
Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.肥胖的强化行为治疗联合利拉鲁肽 3.0mg:一项随机对照试验。
Obesity (Silver Spring). 2019 Jan;27(1):75-86. doi: 10.1002/oby.22359. Epub 2018 Nov 13.
8
A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite.氯卡色林与生活方式咨询用于维持体重减轻的随机对照试验:与情绪和压力相关的饮食、食物渴望及食欲的变化
Clin Obes. 2018 Dec;8(6):383-390. doi: 10.1111/cob.12279. Epub 2018 Sep 17.
9
Causal Attributions for Obesity Among Patients Seeking Surgical Versus Behavioral/Pharmacological Weight Loss Treatment.寻求手术与行为/药物减肥治疗的肥胖患者对肥胖原因的归因。
Obes Surg. 2018 Nov;28(11):3724-3728. doi: 10.1007/s11695-018-3490-7.
10
"Last Supper" Predicts Greater Weight Loss Early in Obesity Treatment, but Not Enough to Offset Initial Gains.“最后的晚餐”预示着肥胖治疗早期体重会有更大幅度下降,但不足以抵消初始体重增加。
Front Psychol. 2018 Aug 2;9:1335. doi: 10.3389/fpsyg.2018.01335. eCollection 2018.